BackBioGend Therapeutics , Ltd. Overview

BioGend Therapeutics , Ltd. Current Cash

Track BioGend Therapeutics , Ltd.'s current cash ($150M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$149.79M
↓ 33.59% YoYΔ $-75.77M vs prior year quarter

Peer trimmed avg / median

Loading

BioGend Therapeutics , Ltd. Current Cash History

Loading

BioGend Therapeutics , Ltd. vs. peers: Current Cash Comparison

Loading

BioGend Therapeutics , Ltd. Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BioGend Therapeutics , Ltd. (6733.TWO) FAQ

As of the most recent data (June 2026), 6733.TWO shows a current cash of $150M. That compares with $230M in the prior-year period — down 33.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 6733.TWO's current cash is now $150M (was $230M) — a 33.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether BioGend Therapeutics , Ltd. is outperforming or lagging.

Tracking 6733.TWO's current cash over time shows whether BioGend Therapeutics , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $150M That compares with $230M in the prior-year period — down 33.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has BioGend Therapeutics , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $150M) with ownership activity and broader fundamentals.

BioGend Therapeutics , Ltd.'s current cash is $150M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.